全文获取类型
收费全文 | 153588篇 |
免费 | 32403篇 |
国内免费 | 2408篇 |
专业分类
耳鼻咽喉 | 5216篇 |
儿科学 | 5436篇 |
妇产科学 | 2410篇 |
基础医学 | 3585篇 |
口腔科学 | 1571篇 |
临床医学 | 27067篇 |
内科学 | 48068篇 |
皮肤病学 | 7543篇 |
神经病学 | 15030篇 |
特种医学 | 6647篇 |
外科学 | 41608篇 |
综合类 | 256篇 |
现状与发展 | 72篇 |
一般理论 | 5篇 |
预防医学 | 7252篇 |
眼科学 | 3520篇 |
药学 | 1179篇 |
中国医学 | 11篇 |
肿瘤学 | 11923篇 |
出版年
2024年 | 687篇 |
2023年 | 4815篇 |
2022年 | 1250篇 |
2021年 | 3170篇 |
2020年 | 6071篇 |
2019年 | 2250篇 |
2018年 | 7492篇 |
2017年 | 7417篇 |
2016年 | 8526篇 |
2015年 | 8544篇 |
2014年 | 15629篇 |
2013年 | 15838篇 |
2012年 | 5741篇 |
2011年 | 5769篇 |
2010年 | 10516篇 |
2009年 | 14380篇 |
2008年 | 5979篇 |
2007年 | 4229篇 |
2006年 | 6710篇 |
2005年 | 3949篇 |
2004年 | 3185篇 |
2003年 | 2192篇 |
2002年 | 2221篇 |
2001年 | 3847篇 |
2000年 | 3058篇 |
1999年 | 3247篇 |
1998年 | 3676篇 |
1997年 | 3490篇 |
1996年 | 3376篇 |
1995年 | 3223篇 |
1994年 | 1954篇 |
1993年 | 1571篇 |
1992年 | 1402篇 |
1991年 | 1441篇 |
1990年 | 1079篇 |
1989年 | 1194篇 |
1988年 | 1041篇 |
1987年 | 869篇 |
1986年 | 895篇 |
1985年 | 728篇 |
1984年 | 563篇 |
1983年 | 536篇 |
1982年 | 519篇 |
1981年 | 408篇 |
1980年 | 366篇 |
1979年 | 316篇 |
1978年 | 337篇 |
1977年 | 405篇 |
1975年 | 285篇 |
1972年 | 315篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
77.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.78.
Status migrainosus is defined by the international classification of headache disorders (ICHD) criteria as a debilitating migraine lasting more then 72 hours. The epidemiology of status migrainosus is still unknown in adult and children, and frequently underdiagnosed. Children and adolescents often end up in the emergency room with an intractable headache that failed outpatient therapy. Six to seven percent of these children do not respond to acute infusion therapy and require hospitalization. It is imperative that more aggressive therapy is considered when patients are affected by a severe intractable headache to prevent further disability and returning the child to baseline activity. Multiple therapies are available for adults and children. Studies for acute therapy in the emergency room are available in adults and pediatric groups. Small studies are available for inpatient therapy in children and, along with available therapies for children and adolescents, are described in this review. A review of the literature shows growing evidence regarding the use of dihydroergotamine intravenously once patients are hospitalized. Effectiveness and safety have been proven in the last decades in adults and small studies in the pediatric populations. 相似文献
79.
80.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255